In Vivo Selection of HIV-1 Variants with Reduced Susceptibility to the Protease Inhibitor L-735,524 and Related Compounds
Part of the
Advances in Experimental Medicine and Biology
book series (AEMB, volume 394)
The human immunodeficiency virus type 1 (HIV-1) is a lentivirus that establishes a persistent, long-term infection in its human host. Like all members of this retroviral subfamily, it completes its replication cycle predominantly by budding from the plasma membrane of the infected cell. The newly formed viral particle contains a core that is composed of two copies of the viral genomic RNA and multiple copies of two precursor polyproteins. During or immediately after budding, the polyproteins are cut into subunmits by a virus-specified protease to yield the mature viral core proteins, which include the matrix, capsid and nucleocapsid proteins as well as the viral protease, reverse transcriptase and integrase enzymes. A mature core is essential for viral infectivity. Elimination of virus protease activity through directed mutation of the protease gene results in production of noninfectious mutant viral particles with immature, unprocessed cores.1 Accordingly, the protease is a suitable target for the development of antiviral agents designed to prevent ongoing cycles of the persistent infection.
KeywordsProtease Gene Human Immunodeficiency Virus Protease Amino Acid Alteration Inhibit Virus Replication Hydroxy Amino
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Kohl NE, Emini EA, Schleif WA et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA, 1988; 85: 4686–4690.PubMedCrossRefGoogle Scholar
Toh H, Ono M, Saigo K et al. Retroviral protease-like sequence in the yeast transposon Tyl. Nature, 1985; 315: 691–692.CrossRefGoogle Scholar
Pearl LH and Taylor WR A structural model for the retroviral proteases. Nature, 1987; 329: 351–354.PubMedCrossRefGoogle Scholar
Darke PL, Nutt RF, Brady SF et al. HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. Biochem. Biophys. Res. Commun., 1988; 156: 297–303.PubMedCrossRefGoogle Scholar
Kotler M, Katz RA, Danho W et al. Synthetic peptides as substrates and inhibitors of a retroviral protease. Proc Natl Acad Sci USA, 1988; 85: 4185–4189.PubMedCrossRefGoogle Scholar
Lillehoj EP, Salazar FHR, Mervis RI et al. Purification and structural characterization of the putative gag-pol protease of human immunodeficiency virus. J Virol, 1988; 62: 3053–3058.PubMedGoogle Scholar
Huff JR HIV protease: A novel chemotherapeutic target for AIDS. J Med Chem, 1991; 34: 2305–2314.PubMedCrossRefGoogle Scholar
Vacca JP, Dorsey BD, Schleif WA et al. L-735,524, an orally bioavailable HIV-1 protease inhibitor. Proc Natl Acad.Sci USA., 1994; 91: 4096–4100.PubMedCrossRefGoogle Scholar
© Springer Science+Business Media New York 1996